Publications
5808 Results
- Journal / Conference
- Blood Advances Oct 22;3(20): 3132-3135
- Year
- 2019
- Research Committee(s)
- Lymphoma
- PMID
- PMID31648328
- PMC
- PMC6849956
- Study Number(s)
- S1106
Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma [Brief Reports]
- Journal / Conference
- JAMA Open Network Sep 4;2(9):e1910593
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID31483471
- PMC
- PMC6727679
Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications
- Journal / Conference
- Health and Quality of Life Outcomes Aug 22;17(1):146
- Year
- 2019
- Research Committee(s)
- Genitourinary
- PMID
- PMID31438967
- PMC
- PMC6704545
- Study Number(s)
- S9916
A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events
- Journal / Conference
- Kidney Cancer Aug 7;3(2):111-118
- Year
- 2019
- Research Committee(s)
- Genitourinary
- PMID
- PMID31763512
- PMC
- PMC6864417
- Study Number(s)
- S0931
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
- Journal / Conference
- Chest Mar;155(3):502-509
- Year
- 2019
- Research Committee(s)
- Lung
- PMID
- PMID30391190
- PMC
- PMC6435782
- Study Number(s)
- S9900
The accuracy of clinical staging of stage I-III non-small cell lung cancer: An analysis based on individual participant data [on behalf of the NSCLC Meta-analysis Collaborative Group (K Kelly)]
- Journal / Conference
- JAMA Oncology Sep 5;5(11):1582-1588; Sep 5;. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print]
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID31486832
- PMC
- PMC6735405
- Study Number(s)
- CTSU/C80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial
- Journal / Conference
- Journal of Clinical Oncology Oct 10;37(29):2620-2631
- Year
- 2019
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID31408415
- PMC
- PMC6900834
- Study Number(s)
- CTSU/C80405
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB(Alliance)/SWOG 80405
- Journal / Conference
- JAMA Internal Medicine Oct 1;179(10):1440
- Year
- 2019
- Research Committee(s)
- Cancer Control
- PMID
- PMID31589258
- Study Number(s)
- SWOG-9217
5a-Reductase Inhibitor Use in Patients With Prostate Cancer [Letter to the Editor/Comment & Response] re: Sarkar RR, Parsons JK, Bryant AK, et al.]
- Journal / Conference
- Journal of Clinical Oncology Sep 10;37(26):2338-2348. doi: 10.1200/JCO.19.00647. Epub 2019 Jul 24.
- Year
- 2019
- Research Committee(s)
- Breast
- PMID
- PMID31339827
- PMC
- PMC6900836
Adjuvant Chemotherapy with Standard Regimens versus Capecitabine in Older Women with Early Stage Breast Cancer: 10-year update of Alliance/CALGB trial 49907
- Journal / Conference
- American College of Clinical Pharmacology (9/15-17/2019, Chicago, IL), poster
- Year
- 2019
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S0528, S0711